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Abstract
Background: Safe and efficient vector systems for delivering antigens or immunomodulatory molecules to
dendritic cells (DCs), T lymphocytes or both are considered effective means of eliciting adaptive immune
responses and modulating their type, extent, and duration. As a possible tool toward this end, we have developed
a self-inactivating vector derived from feline immunodeficiency virus (FIV) showing performance characteristics
similar to human immunodeficiency virus-derived vectors but devoid of the safety concerns these vectors have
raised.
Methods: The pseudotyped FIV particles were generated with a three-plasmid system consisting of: the
packaging construct, providing Gag, Pol and the accessory proteins; the vector(s), basically containing FIV
packaging signal (ψ), Rev responsive element, R-U5 region at both ends, and the green fluorescent protein as
reporter gene; and the Env plasmid, encoding the G protein of vesicular stomatitis virus (VSV-G) or the chimeric
RD114 protein. Both packaging and vector constructs were derived from p34TF10, a replication competent
molecular clone of FIV. The pseudotyped particles were produced by transient transfection in the Crandell feline
fibroblast kidney (CrFK) or the human epithelial (293T) cell line.
Results: To broaden its species tropism, the final vector construct was achieved through a series of intermediate
constructs bearing a longer ψ, the FIV central polypurin tract sequence (cPPT), or the woodchuck hepatitis post-
regulatory element (WPRE). These constructs were compared for efficiency and duration of transduction in CrFK
or 293T cells and in the murine fibroblast cell line NIH-3T3. Whereas ψ elongation and cPPT addition did not
bring any obvious benefit, insertion of WPRE downstream GFP greatly improved vector performances. To
maximize the efficiency of transduction for ex-vivo murine DCs and T-lymphocytes, this construct was tested
with VSV-G or RD114 and using different transduction protocols. The results indicated that the FIV construct
derived herein stably transduced both cell types, provided that appropriate vector makeup and transduction
protocol were used. Further, transduced DCs underwent changes suggestive of an induced maturation.
Conclusion: In contrast to previously described FIV vectors that were poorly efficient in delivering genetic
material to DCs and T lymphocytes, the vector developed herein has potential for use in experimental
immunization strategies.
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Upon encountering foreign invaders, dendritic cells
(DCs) in the periphery of the body undergo a dynamic
and coordinated reprogramming of gene expression, sur-
face phenotype and cellular function [1]. While this mat-
uration is ongoing, DCs migrate to lymphoid organs
where they interact with T lymphocytes which, in turn,
decode the DC message to start a cascade of events ulti-
mately leading to immune responses against the invading
antigens. Thus, at least theoretically, safe and effective sys-
tems for delivering antigenic and/or adjuvant proteins/
genes to DCs, T cells or both represent valuable means of
eliciting and modulating type, extent, and duration of
adaptive immune responses [2]. Although initial attempts
to achieve this goal using conventional methods were dis-
appointing, recent advances have opened new and more
promising avenues [3,4].
Viruses are considered ideal for delivering transgenes due
to their inherent ability to bring genetic material into cells
but need extensive engineering to overcome limitations
such as the spectrum of cells they can enter and the nox-
ious effects they may exert. For example, adenoviral vec-
tors have been shown to be effective at transducing DCs
and T lymphocytes [5] but, on a negative side, they have
been seen to induce massive production of proinflamma-
tory cytokines and robust vector-specific immune
responses [6]. On the other hand, oncoretroviral vectors
interfere minimally with normal body and cell functions
but are poor at transducing nondividing and rarely divid-
ing cells, such as DCs and resting T cells.
Consistent with the ability of lentiviral genomes to reach
the nucleus of host cells even if these do not divide [7],
vectors derived from the human immunodeficiency virus
(HIV) have been found to transduce DCs and T cells at
high efficiency [8-11]. In their current versions, HIV vec-
tors have most of the original viral genome deleted,
including some transcriptional elements in the U3 region
of the 3' long terminal repeat (LTR) of the DNA used to
produce the vector RNA. During reverse transcription, this
deletion is transferred to the 5' LTR of the proviral DNA,
thus generating two LTRs which are mostly inactive (self-
inactivating [SIN] vectors). Also, these vectors are pro-
duced using multiple constructs encoding different com-
ponents to minimize the risk of generating replication-
competent viruses.
Because of safety concerns [12], vectors derived from the
feline immunodeficiency virus (FIV) are considered a
good alternative to the HIV vectors because FIV has never
been detected in animal species other than domestic and
wild cats and has similar genome organization but mini-
mal sequence homology to HIV, thus minimizing the risk
of unwanted recombinations [13].
The FIV vectors described to date have been very successful
at delivering transgenes into a variety of cells of different
animal species [reviewed in [12]] but have performed
poorly when used to transduce DCs, T lymphocytes and
non-adherent white blood cells in general [14-16]. In this
report, we describe a SIN FIV vector that effectively trans-
duces ex vivo murine DCs and T cells.
Methods
Parental plasmid and strategy used for packaging and 
vector construction
Prototype vectors and packaging construct were devel-
oped from p∆00 (Fig. 1A and 2A), a replication-compe-
tent molecular clone of the Petaluma strain of FIV (FIV-
Pet), derived from plasmid p34TF10 [GenBank:
NC_001482] and produced in our laboratory by substitut-
ing a tryptophan codon for the stop codon in the acces-
sory gene ORF-A [17]. As reported [18], an intact ORF-A is
essential for optimal FIV replication in lymphoid cells.
Nucleotide (nt) positions of packaging and vector con-
structs are referred to the NC_001482 sequence. The
sequence of primers used in polymerase chain reaction
(PCR) is available by e-mail on request. All the intermedi-
ate and final constructs described below were checked for
proper insertions and absence of unwanted mutations by
cycle sequencing using an automated DNA sequencer (GE
Healthcare, Milan, Italy). All vectors were tested using
enhanced green fluorescent protein (GFP) as reporter
molecule.
Packaging constructs
Four packaging constructs were developed and tested.
Due to minimal activity of the FIV LTR in non feline cells
[19], all constructs had the 5' and 3' LTRs of p∆00 replaced
with cytomegalovirus early promoter (CMVp) and bovine
growth hormone poly A, respectively. Also, deletion of the
5'LTR was extended to nt position 507 to remove most of
the RNA packaging site (ψ). From this intermediate con-
struct the packaging constructs were produced as follows:
p∆env1, retaining the Rev and Rev-responsive element
(RRE), necessary for the nuclear export of Gag-Pol mRNA,
and containing an internal 1,044 nt deletion within env
(nt position 7246–8289) obtained by digestion with the
restriction enzymes BclI and SpeI (New England Biolabs,
Celbio, Milan, Italy), filling up the protruding ends with
Klenow DNA polymerase (New England Biolabs) and
joining of resulting blunt-ends with T4 DNA ligase (Fer-
mentas, M-Medical, Milan, Italy) (Fig. 1B).
p∆env2, retaining the Rev and RRE but with the internal
env deletion extended from end of the first exon Rev to
beginning of RRE (nt position 7246–8289). This deletion
was created by PCR using overlapping primers (Fig. 1C).Page 2 of 13
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A, env, rev and RRE. This genome portion was removed by
digestion with the restriction enzymes BspMII (nt position
5327) and BlpI (nt position 9203). The Rev/RRE system
was replaced by introducing the Mason-Pfizer monkey
virus constitutive transport element (CTE) downstream vif
(Fig. 1D).
pGP-RRE, having the same deletion as pGP-CTE and con-
taining RRE (nt position 8642–9067), retrieved by PCR
from p∆00, in place of CTE (Fig. 1E). The Rev/RRE system
was restored by providing Rev in trans.
Vector constructs
The following vector constructs were developed and
tested:
LA34, produced from p∆00 by sequential steps as follows:
the U3 region of the 5' LTR (nt position 1–203, as referred
to NC_001482) was replaced with pCMV amplified from
Schematic representation of the FIV vector constructs usedFigure 2
Schematic representation of the FIV vector con-
structs used. A) Parental clone p∆00. B) Prototype LA34 
vector: minimal, self-inactivating vector with both the U3 
LTR domains deleted and devoid of all accessory and struc-
tural proteins except ψ, a 120 nt stretch at the of 5'-end gag 
containing the domains important for RNA encapsidation, 
and the RRE. MCS, the multiple cloning site, contains the 
CMVp-GFP cassette used as reported gene for all vectors. C) 
LA34-cPPT, vector derived from LA34 by inserting the cen-
tral poly-purine tract (cPPT), important for nuclear import of 
the FIV preintegration complex, between RRE and MCS. D) 
LAW34, vector obtained by inserting the woodchuck post-
trascription regulatory element (WPRE) in LA34 down-
stream MCS. Variant vectors having a longer (310 nt) gag 
fragment (LA34-L and LAW34-L, respectively) were also 
produced but are not shown. Total size indicates the number 
of nucleotides of the vector without the CMVp-GFP cassette.
Schematic representation of the FIV packaging constructs usedFigure 1
Schematic representation of the FIV packaging con-
structs used. A) Parental clone p∆00. B) Packaging con-
struct p∆env1; the 5' and 3' LTRs are replaced by CMVp and 
bovine growth hormone (BGH) poly A, respectively, ψ is 
partially deleted, and env is deleted by an internal 1 Kbp. C) 
Packaging construct p∆env2; derived from p∆env1 by remov-
ing the entire env except for the terminal ends overlapping 
the first exon rev and the Rev-responsive element (RRE) nec-
essary for nuclear export of unspliced viral RNAs; D) Packag-
ing construct pGP-CTE; obtained by deleting from within vif 
to BGH poly A, and replacing the Rev-RRE system with the 
Mason-Pfizer monkey virus constitutive transporting element 
(CTE); E) Packaging construct pGP-RRE; derived from pGP-
CTE by replacing the CTE with the RRE retrieved by amplifi-
cation from the parental clone p∆00. For this construct, Rev 
was provided in trans.Page 3 of 13
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Italy) by digestion with the restriction enzymes PshAI and
SacI (New England Biolabs). To prevent LTR regeneration
during reverse transcription, an internal 120 bp segment
of U3 in the 3'LTR (nt position 9201–9320), containing
the cis-acting transcriptional elements AP-1, AP-4 and
ATF-binding sites and TATA box [20], was also removed
by PCR using overlapping primers. The same strategy was
applied to delete the region from nt position 749 to 9045,
encompassing most of the gag and the entire pol and env
genes. Finally, the env segment containing RRE (nt posi-
tion 8650–9038) was inserted downstream the gag stretch
together with a multiple cloning site (MCS) containing
AsuII, ClaI, SacII, BlpI, KpnI, and PacI restriction sites, and
used herein for cloning the reporter GFP gene (Fig. 2B).
LA34-cPPT, obtained by inserting the central poly-purine
tract (cPPT, nt position 4945–5071) that in FIV is local-
ized within pol and is important for nuclear import of the
preintegration complex (PIC) [21], in LA34. The cPPT was
retrieved by PCR from p∆00 and inserted between RRE
and MCS (Fig. 2C).
LAW34, obtained by inserting the woodchuck hepatitis
post-transcriptional regulatory element (WPRE; kind gift
of Dr. Stefano Indraccolo, University of Padua, Italy) in
LA34 downstream MCS (Fig. 2D).
LA34L and LAW34L, variants of the above LA34 and
LAW34, respectively, in which the gag stretch was
extended from the original 120 nt (nt position 628–747)
to 310 nt (628–937) by a two step PCR. They were pre-
pared because reports [22,23] have suggested that, in FIV,
gag domains downstream the main ψ determinants may
contribute to efficient RNA encapsidation.
Other plasmids
The Rev provided in trans to the pGP-RRE was obtained by
amplifying the corresponding mRNA from RNA of FIV-Pet
infected Crandell feline kidney fibroblast (CrFK) cells.
The cDNA was then cloned into the pcDNA3.1 plasmid
(pcDNA-Rev). Constructs pcDNA-Rev and pGP-RRE were
cotransfected at equimolecular ratio. FIV particles were
pseudotyped with the vesicular stomatitis virus glycopro-
tein envelope (Env) VSV-G (495 amino acids [aa]) or the
chimeric retrovirus glycoprotein RD114/TR (546 aa) [24].
VSV-G was encoded by pCMV-VSV-G derived from the
pcDNA3.1 plasmid and RD114/TR by the phCMV-
RD114/TR plasmid (kind gift of Dr. François-Loic Cosset,
Ecole Normale Supérieure, Lyon, France).
Cell lines and primary murine cells
The cells used included the CrFK, highly permissive to
FIV-Pet, and the human epithelial 293T and murine
fibroblast NIH-3T3, two nonfeline lines that do not per-
mit FIV replication. All cells were propagated in Dul-
becco's modified Eagle medium (D-MEM, Sigma-Aldrich,
Milan, Italy) supplemented with 10% fetal calf serum
(FCS), 100 U/ml penicillin, 100 µg/ml streptomycin and
2 mM L-glutamine (Sigma-Aldrich), at 37°C in 5% CO2.
Murine DCs were generated from the bone marrow (BM)
of 6- to 10-week old BALB/c mice. Briefly, BM cells were
flushed from the femurs, filtered through a 200 µm mesh
to remove fibrous tissues, and cleared from erythrocytes
with ammonium chloride. Residual cells were cultured at
2 × 106 cells/ml in complete RPMI 1640 medium (Sigma-
Aldrich), supplemented with 10% FCS, penicillin-strepto-
mycin and glutamine, and induced to differentiate into
DCs with 20 ng/ml recombinant mouse granulocyte mac-
rophage colony-stimulating factor (GM-CSF) and 5 ng/ml
recombinant mouse interleukin (IL)-4. Floating cells were
removed, and fresh GM-CSF/IL-4 enriched medium was
added at days 3 and 5 of culture. On day 7, non-adherent
and loosely adherent DCs were collected and analyzed by
flow cytometry. While control cells cultured with no GM-
CSF and IL-4 were essentially negative, they were 55%
CD11c-positive, 70% CD80-positive and 15% CD40-pos-
itive, thus exhibiting the expression profile of immature
DCs [25]. Microscopic examination of the cultures also
revealed that they were rich in cells with DC morphology.
Murine T lymphoblasts were produced by concanavalin A
stimulation of spleen cells from the same mice. Briefly,
spleen cells were cultured at 2 × 106/ml in 6-well plates for
5 days in complete RPMI 1640 medium supplemented
with 50 unit/ml IL-2, 10% FCS, penicillin-streptomycin,
and glutamine. These cells were 30% CD4 positive and
12% CD8 positive.
Vector production
Vectors were generated in CrFK or 293T cells. Briefly, 2.8
× 106 cells were seeded in 10 cm Petri dishes and one day
later co-transfected with one of the vector plasmids,
p∆env1, and either the VSV-G or the RD114/TR Env
(4:5:1; 20 µg total DNA) using a modified calcium phos-
phate method [26]. Transfection efficiency was evaluated
48 h later by counting GFP-positive cells by flow cytome-
try with a FACScan and a CELLQuest Version 2 software
(BD Biosciences, Milan, Italy). Vector content in the cul-
ture fluids collected on the same day was determined by
measuring FIV p25 capsid protein and the number of FIV
RNA genome copies as previously described [26,27], fol-
lowing clarification at 1,500 rpm for 10 min and 0.45 µm
filtration. Supernatants were aliquoted in 1 ml volume
and stored at -80°C until use.
Standard transduction protocol
The day before transduction, 24-well plates were seeded
with 7 × 104 293T cells, 5 × 104 CrFK cells, 5 × 104 NIH3T3
cells, 5 × 105 DCs, or 2 × 106 T lymphoblasts per well in 1
ml complete medium. Eighteen h later, the medium wasPage 4 of 13
(page number not for citation purposes)
Genetic Vaccines and Therapy 2007, 5:8 http://www.gvt-journal.com/content/5/1/8replaced with the same volume of vector suspension.
Transduction efficiency was evaluated by counting GFP
positive cells by flow cytometry 2 days post-transduction
(PT).
FIV vector titer
Vector titers were determined in 293T cells and expressed
as number of transduction units (TU) per ml. Briefly, 7 ×
104 cells were transduced as described above with the vec-
tor preparation under test serially diluted 10-fold in cul-
ture medium. Two days later, the cells were harvested and
analyzed for GFP fluorescence by flow cytometry. Each
dilution was tested in triplicate.
FIV vector safety evaluation
Nucleic acids in supernatants, collected from transfected
293T cells and treated as described under "Vector produc-
tion", were extracted using the QIAamp Viral RNA kit
(Qiagen, Milan, Italy). Genomic DNA and RNA from 6 ×
104 transfected or transduced 293T cells were extracted
with QIAamp DNA Blood Kit and RNeasy kit (Qiagen),
respectively. Viral and genomic RNAs were treated with
RNase-free DNase (Qiagen) to eliminate residual DNA.
Presence of p∆env1 plasmid and RNA transcripts in super-
natants and transduced cells was investigated by PCR
using 295s-296as primers targeting FIV p25 capsid protein
(Fig. 3A). Translocation of the U3 deletion from the 3' to
the 5'LTR in the vector provirus was examined by amplify-
ing genomic DNA from transduced cells with U3s-R3as
primers (Fig. 3B). Inactivation of LTR mediated transcrip-
tion was ascertained by amplifying cDNA of transduced
cells with INs and RREas primers (Fig. 3C). Reverse tran-
scription was carried out with an avian myeloblastosis
virus reverse trascriptase (RT) (Finnzyme, Celbio, Milan
Italy) and the specific antisense. Amplification profiles
were as follows: initial denaturation 94°C 2 minutes;
cycling 94°C 30 seconds, 60°C (54°C for 295s-296as) 30
seconds, 72°C 30 seconds (40 seconds for 295s-296as),
35 cycles; extension 72°C 10 minutes. The 5'LTR ampli-
con was cycle sequenced using the automated ALF Expres-
sII DNA sequencer (GE Healthcare, Cologno Monzese,
Italy).
Results
Genome organization of the packaging and vector 
constructs
Packaging and vector constructs were both derived from
p∆00, a replication competent clone of FIV-Pet (Fig. 1A
and 2A).
The packaging constructs provided Gag and Pol and were
under the control of the CMVp. Basically, they lacked the
untranslated 5'LTR-gag region that, together with the ini-
tial part of gag, form the ψ signal required for viral RNA
encapsidation into assembling virions and were deleted of
part (p∆env1 and p∆env2 constructs) or the entire (pGP-
CTE and pGP-RRE) env. The latter constructs also lacked
Vif, ORF-A, and Rev. Since nuclear export of unspliced
(i.e. Gag-Pol encoding mRNA) and singly spliced mRNAs
occurs through Rev binding to the RRE motif, in pGP-CTE
the Rev/RRE system was replaced by a CTE and in pGP-
RRE RRE was maintained and Rev provided in trans by
cotransfection of pcDNA-RRE plasmid (Fig. 1B–1D).
Safety evaluation of packaging and vector constructsFigure 3
Safety evaluation of packaging and vector constructs. 
A) p∆env1 transportation from transfected to transduced 
cells as evaluated by gag p25 PCR using the indicated prim-
ers. Lane A: DNA from transfected 293T cells; lane B: no 
template control; lanes C and D: DNA and RNA from trans-
duced 293T cells; lane E: DNA from mock transfected cells. 
B) Translocation of the U3 deletion to the 5'LTR, as checked 
by PCR using primers annealing to the beginning U3 and 
within the R region of LA34 proviral DNA. Lane A: p∆00 
plasmid (full-length LTR), lane B: no template control; lane C: 
DNA from transduced 293T cells, lane D: DNA from mock 
transduced cells. C) Analysis of LTR directed transcription as 
tested by PCR using primers upstream the GFP promoter. 
Lane A: DNA of transduced 293T cells; lane B: no template 
control; lanes C and D: RNA from transduced 293T cells 
with and without DNase treatment prior to reverse tran-
scription; lanes E and F: RNA from mock transduced cells 
treated as for C and D. Primer nt position referred to the 
NC_001482 sequence. M1: 100 base-pair ladder, M2: Gene 
ruler 1 Kb DNA ladder (GE Healthcare).Page 5 of 13
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CMVp and had few remnants of the FIV genome, namely
1) the ψ signal, 2) the RRE motif, placed downstream ψ
and interacting with the Rev provided by the packaging
construct or pcDNA-RRE, 3) the untranslated region
between env and 3'LTR, and 4) the two LTRs, both deleted
of the U3 domain to avoid the generation of functional
LTRs during reverse transcription. Due to extensive rear-
rangement and deletions, LA34 was 2.2 Kb in size.
Packaging and vector constructs are safe and stable
The packaging constructs (Fig. 1B–1E) were developed
and tested for stability and safety (non-infectivity) in CrFK
and 293T cells. Briefly, the packaging constructs were
transfected into cells which were propagated for at least
two weeks and monitored twice a week for FIV p25 and
viral RNA release into supernatant. Further, cell-free
supernatants were collected at 7 and 14 days post-trans-
fection, and seeded into fresh CrFK cell that were culti-
vated for additional two weeks. Except for a low and
transient production of p25 found two-three days post-
transfection, neither FIV RNA nor infectious particles were
found in supernatants (data not shown). The results indi-
cated that the packaging constructs were free from residual
p∆00 plasmid molecules, were stable, and did not gener-
ate infectious virus.
Transduction efficiency, stability, and safety were tested in
CrFK and 293T cells, using LA34 pseudotyped with VSV-G
(LA34/VSV-G) generated in CrFK or 293T cells with
p∆env1 as packaging construct. The proportions of GFP-
positive CrFK and 293T cells 2 days post-transfection were
generally greater than 75%. As determined by measuring
p25 and number of vector RNA copies in the supernatant
from day 2 to 7 post-transfection, LA34/VSV-G produc-
tion peaked at day 2 or 3 (data not shown). Vector parti-
cles collected at these times were pelleted by
ultracentrifugation and analyzed by western blot for pro-
tein content. Regardless of whether produced in CrFK or
293T cells, the vector generated protein patterns that, with
the obvious exception of Env, were identical to the one of
whole FIV-Pet virus used as control, indicating that proper
generation and maturation of virions had taken place
(data not shown). As shown in Table 1, vector titers
exceeded 109 RNA copies/ml and 106 TU/ml in 293T cells
and were slightly higher when the vector was produced in
CrFK rather than 293T cells.
Vector safety was evaluated by several approaches. First,
the progeny particles were checked for p∆env1 incorpora-
tion by testing them as well as transduced cells for a gag
p25 sequence contained in the packaging construct only
(Fig. 1B to 1E). The 674 bp amplicon generated by the
PCR and RT-PCR assays used was readily detected in the
DNA of transfected cells (positive control) but uniformly
absent in the vector particles (not shown) and in trans-
duced cells (Fig. 3A). Second, it was checked whether the
U3 deletion, created in the 3'LTR of the vector construct,
was indeed translocated to the 5'LTR of proviral DNA by
using primers that generated amplicons of different sizes
from the full-length (352 bp) and the U3 deleted LTRs
(232 bp). The amplicon generated from the DNA of trans-
duced cells was clearly smaller than the one generated
from the p∆00 plasmid used as a source of full-length LTR
(Fig. 3B) and had the sequence expected for the deleted
LTR (not shown). Third, functional inactivation of the 5'
LTR was checked by examining transduced cells for LA34
RNA genomes, the transcription of which would have
required a full-length 5'LTR. As shown by Fig. 3C, while
the DNA of transduced cells was clearly positive for LA34
sequences, the RNA obtained from the same cells was uni-
formly negative, regardless of whether it was digested or
not with RNase-free DNase. Collectively, these findings
demonstrated that LA34 is indeed a SIN vector, that the
pseudotyped particles it generates are safe, and that no
vector RNA is produced by LA34 transduced cells.
LA34 is best packaged by p∆env1 and preferentially 
transduces feline cells
The packaging constructs were tested for ability to pro-
duce LA34/VSV-G virions in 293T cells that were trans-
fected with equimolecular amounts of packaging, vector,
and VSV-G plasmids. Supernatants collected 2 days post-
transfection were analyzed for virus release by measuring
p25 and vector RNA genome copies and for competence
for transduction in 293T cells. The efficiency of transfec-
tion was similar for all plasmid combinations and aver-
aged 80%. As shown in Table 2, LA34/VSV-G production
with p∆env1 and p∆env2 was very high, as shown by the
high levels of p25 produced, 109 vector RNA copies and
106 TU/ml. In contrast, both vector RNA and TU titers of
VSV-G pseudotyped particles produced by using pGP-RRE
and pGP-CTE were one and two logs lower, respectively,
suggesting that virus release, rather than infectivity, was
less efficient. The pseudotyped particles generated with
p∆env1 and p∆env2 were further tested for transduction
in CrFK. Since the LA34/VSV-G generated with p∆env1
performed slightly better in this cell subtype, this con-
struct was selected as packaging for subsequent experi-
ments (data not shown).
Transduction efficiency and duration of transgene expres-
sion were assessed by inoculating LA34/VSV-G produced
in 293T cells into CrFK, 293T and NIH-3T3 cultures at var-
ying RNA copy numbers. The best results were obtained
with 109 copies, corresponding roughly to 10 TU/cell,
which at the first readout, 4 days PT, transduced 66% and
52% of CrFK and 293T cells, respectively. In contrast,
GFP-positive NIH-3T3 cells rarely exceeded 20%, indicat-
ing that these cells were largely refractory to transductionPage 6 of 13
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tion, GFP-positive cell numbers remained essentially
unchanged regardless of initial transduction level, indicat-
ing that transduction and transgene expression were sta-
ble, as a likely result of vector integration into the cell
genomes (Fig. 4A). No infectious virus was detected in the
transduced cultures at any time, not even after passaging
the culture fluids in fresh CrFK cells repeatedly (data not
shown).
Insertion of the post-transcription regulatory element 
WPRE increases LA34 transduction efficiency for NIH-3T3
Because the findings above were indicative of a preferen-
tial ability of LA34 to transduce feline CrFK cells relative
to the non feline cells 293T and NIH-3T3, we made efforts
to widen its breadth of action by improving nuclear trans-
location of PIC, stabilization of transgene mRNAs, and
incorporation of vector RNA into pseudotyped particles
that are major determinants of lentiviral cell transduction
and transgene expression [28]. Two short single-stranded
regions of the lentiviral genome DNA (flaps) are believed
to optimize viral genome folding, thus enhancing its steric
fit in the nuclear pore [29]. In FIV, one of these flaps is
located upstream the 3' LTR (U3PPT) and the other close
to the 3' end of pol (central PPT, cPPT) [21]. Since LA34
contains only the U3PPT, we inserted the cPPT between
RRE and MCS (construct LA34-cPPT, Fig. 2C), similar to
what already done in the FIV vectors developed in previ-
ous reports [28,30]. However, the change had no appreci-
able effects on vector performance in any of the three cell
lines (Fig. 3B).
When we inserted the RNA transport WPRE element
downstream of MCS in LA34 (LAW34, Fig. 2D), so that it
could be incorporated into transgene mRNA, the effi-
ciency of transduction improved greatly. Compared to
LA34, LAW34 showed similar RNA titers but the TUs per
ml were approximately 1 log higher (Table 1). Most
importantly, LAW34/VSV-G gave rates of NIH-3T3 cell
transduction that were nearly twice as great. In fact, close
to 50% of the latter cells expressed GFP and did so for at
least 4 weeks (Fig. 4B and data not shown).
Recent reports have suggested that the main packaging
domain in the gag of FIV is comprised in a 120 nt stretch
[31]; however, previous studies had suggested the exist-
ence of additional encapsidation determinants in gag,
bringing ψ to about 300 nt in size [23]. We, thus, also con-
structed versions of LA34 and LAW34 having a 311 nt-
long ψ (LA34-L and LAW34-L). When compared to the
respective vectors with 120 nt-long ψ, these versions
showed no appreciably increased titers (data not shown)
and, with the exception of LAW34-L for CrFK cells, had
reduced transduction efficiencies (Fig. 4C). As a result of
these studies, LAW34 was selected for the experiments
below.
Effect of transduction protocol on LAW34 efficiency
In these experiments, we compared the standard transduc-
tion method described under Methods with several proto-
cols that have been shown to increase transduction
efficiency by other vectors. These included: 1) vector ultra-
centrifugation, a procedure frequently used to concentrate
VSV-G pseudotyped viruses that, unlike lentiviral Env-
Table 2: LA34/VSV-G pseudotyped particles generated 2 days 












p∆env1 2.24 9.3 × 109 6.4 × 106
p∆env2 >2.50 3.0 × 109 3.4 × 106
pGP-CTE 1.09 2 × 106 1.0 × 103
pGP-RREc 1.92 8.1 × 108 3.0 × 105
a Average of three independent experiments, mean efficiency of 
transfection 80% (range 75–90%);
b Titer measured in the indicated cells 2 days post-transduction;
c Rev provided in trans by cotransfection of pcDNA-Rev.
Table 1: Vector titers generated from transfected 293T or CrFK cellsa
Vector/Env used for 
pseudotyping
Vector produced in Vector titer (RNA 
copies/ml)
Concentration Transduction units/mlb
LA34/VSV-G CrFK 8.5 × 109 None 3.8 × 106
293T 1.8 × 109 None 1.2 × 106
LAW34/VSV-G 293T 5.0 × 109,c None 2.5 × 107
2.1 × 1010,c Ultracentrifugation 3.0 × 107
293T 7.0 × 109 PBd 3.0 × 107
LAW34/RD114/TR 293T 1.4 × 1010,c Ultracentrifugation 6.0 × 107
4.0 × 109,c PB 1.2 × 108
a Titers measured in supernatants collected 2 days post-transfection, average of three independent experiments.
b Measured in 293T cells.
c Same supernatant, titrated as such or after 10 fold concentration by ultracentrifugation.
d Polybrene.Page 7 of 13
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low-speed centrifugation following poly-L-lysine addition
[33]; 3) addition of polybrene (PB), a polycation that
forms large complexes with viral particles leaving out
nonviral proteins and other factors that may be inhibitory
(protocol PB) [34]; 4) treating the cells with the vector
twice, four h apart (double transduction; protocol DT);
and 5) combined use of 3 and 4 (protocol PB/DT).
LAW34/VSV-G produced in 293T cells (5 × 109 vector
RNA copies/ml) was concentrated 10-fold by ultracentrif-
ugation at 200,000g at 4°C for 2 h. In spite of a 4-fold
increment in vector RNA titer, transduction efficiency was
essentially unchanged relative to the standard method
(Table 1). The same output was observed by using proto-
col 2 in which the virus was concentrated by aggregation
with poly-L-lysine. Moreover, the use of poly-L-lysine
often caused shrinking, granulation, and, occasional
detachment of the cells (data not shown). Protocols 3 to
5 were instead beneficial. A dose-response study of PB in
293T using a vector RNA copy/cell ratio of 200/1 cells
(approx. 10 TU/cell) yielded the highest transduction
rates at 8 µg/ml (Fig. 5A). Importantly, at this dose PB
more than doubled the proportion of transduced NIH-
3T3 cells (Fig. 5B), suggesting that this protocol substan-
tially increased virus infectivity on this cell type. At same
conditions, protocol DT also increased transduction of all
cell types (data not shown). However, protocol DT/PB
was the most effective, since transduced cells exceeded
90% at day 4 (Fig 5B). Overall, the results also underlined
the robustness of LAW34 under various test conditions.
LA34 pseudotyped with RD114/TR transduces NIH-3T3 
cells efficiently
LAW34 was pseudotyped with RD114/TR in 293T cells,
and the vector thus produced (LAW34/RD114/TR; Fig.
6A) was titrated for TU in the same cell substrate using the
ultracentrifugation and the PB/DT protocols. Again, in
spite of a three-fold increment of the vector RNA titer after
supernatant ultracentrifugation, transduction efficiency
was lower compared to the PB protocol, confirming the
modest performances of ultracentrifugation in our hands
(Table 1). LAW34/RD114/TR and LAW34/VSV-G had
essentially same number of vector RNA copies/ml, yet the
former exhibited a 4 fold higher 293T transduction titer
when complexed with PB, confirming the efficacy of this
protocol even in the case of easy-to-transduce cells.
LAW34/RD114/TR and LAW34/VSV-G were also com-
pared for transduction efficiency using the standard pro-
tocol, i.e. with no further manipulations or additions.
Supernatants of packaging 293T cells diluted to achieve a
vector RNA copy/cell ratio 1/200 of either vector per-
formed equally in 293T and CrFK cells even after pro-
longed propagation (Fig. 6B and data not shown). In
contrast, in NIH-3T3 cells LAW34/RD114/TR transduced
with an efficiency the VSV-G counterpart had exhibited
only when used with the PB protocol (Fig. 5B and 6B).
Thus, LAW34/RD114/TR proved effective at transducing
Efficiency and duration of transduction by naïve and variously modified LA34/VSV-G as determined in CrFK, 293T nd NIH-3T3 cellsFigur  4
Efficiency and duration of transduction by naïve and 
variously modified LA34/VSV-G as determined in 
CrFK, 293T and NIH-3T3 cells. A) Efficiency and stability 
of transduction in CrFK (solid columns), 293T (shaded col-
umns) and NIH-3T3 cells (empty columns) as evaluated by 
flow cytometry at the indicated times PT. B) LA34-cPPT 
(shaded columns), LAW34 (empty columns) and LA34 (solid 
columns). Percent GFP-positive cells evaluated by flow 
cytometry 4 days PT. C) LA34-L (shaded columns) and 
LAW34-L (empty columns) versus LA34 (solid columns) and 
LAW34 (striped columns). Percent GFP-positive cells evalu-
ated by flow cytometry 4 days PT. Bars represent the stand-
ard deviation as calculated from three independent 
experiments.Page 8 of 13
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boost transduction efficiency.
LAW34 transduces murine DCs and T lymphocytes 
efficiently
BM-derived DCs were transduced with VSV-G or RD114/
TR pseudotyped LAW34 by using 200 vector RNA copies
per cell and protocols PB, DT, and DT/PB. Cells were
examined 2 days later for GFP expression. LAW34-
RD114/TR transduced much more efficiently than
LAW34/VSV-G, regardless of protocol used. This striking
difference, already clearly evident by microscopic inspec-
tion, was confirmed by flow cytometry analysis of the
cells: whereas the fluorescence signal of LAW34/VSV-G
transduced cells was barely distinguishable from that of
mock transduced cells, LAW34/RD114/TR produced a
clearly defined peak at 101 FL1-H, indicating that most
DCs were transduced and actively expressing GFP (Fig.
7A). In fact, LAW34/RD114/TR performed better with all
3 protocols, transducing up to 52% DCs when the DT/PB
protocol was used versus 17% with LAW/VSV-G (Fig. 7B
and 7C). LAW34/RD114/TR transduction was also exam-
ined for possible effects on markers expression by DCs.
DCs transduced with LAW34/RD114/TR at 200 vector
RNA copies per cell using the PB protocol were compared
to similarly treated cells except that the vector was
replaced by the supernatant of mock-transfected cells. Rel-
ative to mock treated DCs, transduced DCs showed no
changes in CD11c and CD80 expression but underwent a
substantial increase of CD40-positive cells which was
already evident by day 2 PT (Fig. 7D) and lasted through-
out the observation period of 10 days (not shown). Of
note, GFP expression by transduced cells, monitored in
parallel, increased slightly over time (data not shown).
Effect of pseudotyping LAW34 with different EnvFigure 6
Effect of pseudotyping LAW34 with different Env. A) 
Diagrammatic representation of the VSV-G and RD114/TR 
glycoproteins. The latter has the extracellular and transmem-
brane domains of the feline endogenous retrovirus RD114 
and the cytoplasmic tail of an amphotropic murine leukemia 
virus [36]. Numbers are aa residues. B. Transduction effi-
ciency for the indicated cell types of LAW34 pseudotyped 
with VSV-G (solid columns) or RD114/TR Env (empty col-
umns). Bars and percent GFP-positive cells evaluated as in 
Fig. 4.
Evaluation of three transduction protocolsFig re 5
Evaluation of three transduction protocols. A) Effect of 
PB at the indicated concentrations on LA34/VSV-G transduc-
tion of 293T cells. B) Effect of using the standard (empty col-
umns), PB (solid columns) or PB/DT protocol (striped 
columns) on LA34/VSV-G transduction of the indicated cells. 
Bars and percent GFP-positive cells evaluated as in Fig. 4. 
ND, not done.Page 9 of 13
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for ability to transduce cultured murine T lymphoblasts
using the PB or the DT protocol and same vector/cell
ratios. As shown by Fig. 7E and 7F, which reports the read-
ings at day 2 PT, GFP positive cells ranged around 60%
and fluorescence peaks were superimposible regardless of
the Env used for pseudotyping. Also, the use of PB greatly
reduced the efficiency of T lymphoblast transduction by
both LAW34/VSV-G and LAW34-RD114/TR, in spite that
no obvious effects on cell viability were noted. Propor-
tions of CD4 and CD8 positive cells in the cultures
remained stable for at least 10 days, following transduc-
tion (data not shown).
Discussion
Lentivirus-derived vectors possess several advantages,
including that they ensure stable and tightly controlled
expression of transgenes by integrating into the cell
genome, integrate preferentially into actively transcribed
genes yet distantly from cellular promoters [35-37], trans-
duce quiescent and dividing cells alike [7,30,38], and pos-
sibly have a lower insertional mutagenesis risk relative to
vectors derived from other retroviruses [39]. Among such
vectors, those derived from FIV have been shown to be as
efficient as HIV vectors at transducing a variety of cell
types and tissue compartments in vivo and have the added
advantage of posing less safety concerns [12,28]. How-
ever, the FIV vectors described to date performed poorly
when used for transducing immune cells [14-16,40], a
limitation that prompted us to develop an FIV vector that
might efficiently and stably deliver genes into DCs and T
cells.
The vector we first constructed, LA34 is entirely derived
from an FIV strain known to be much attenuated com-
pared to field isolates [17,30] and, to further increase its
safety, is self-inactivated by bearing LTRs partially deleted
and totally inactive. The expression construct could be
easily pseudotyped with two distinct Envs that conferred
either a broad or a more restricted cell tropism. With the
aim to obtain a vector that could be used in mouse mod-
els, efficiency at transducing the murine cell line NIH-3T3
was a major guiding criterion in its design as well as in
optimizing transduction protocol. However, in its origi-
nal format LA34 performed poorly with NIH-3T3 cells.
Thus, in the attempt to overcome this drawback, the fol-
lowing modifications were introduced:
1) lentiviruses have evolved a PIC consisting of cellular
and viral proteins which effectively delivers viral cDNA in
close proximity of the cell genome. Since LA34 lacked
cPPT, one of the two single-strand flaps generated during
reverse transcription that are thought to optimize cDNA
folding and enhance its steric fit in the nuclear pore [29],
we inserted it between RRE and expression cassette. In
contrast to what observed with other FIV vector formats
[28,30], this modification failed to improve LA34 per-
formances. The reason(s) was not addressed, but it is plau-
sible that p34TF10, the parental clone from which LA34
was produced, is per se minimally dependent on this motif
Transduction of primary murine DCs and T lymphocytes with LAW34/VSV-G nd LAW34/RD114/TRFigure 7
Transduction of primary murine DCs and T lym-
phocytes with LAW34/VSV-G and LAW34/RD114/
TR. A) Flow cytometry analysis of DCs transduced with 
LAW34/VSV-G (thick line) or LAW34/RD114/TR (grey area) 
using PB protocol. Dotted line, untransduced, PB-treated 
cells. B) Efficiency of DC transduction by LAW34/VSV-G and 
LAW34/RD114/TR using the 3 protocols indicated. Percent 
GFP positive cells evaluated by flow cytometry 2 days PT. C) 
Intensity of GFP expression in the LAW34/RD114/TR trans-
duced DCs in panel B, using protocols DT (thick line), PB 
(grey area), and DT/PB (grey line). Dotted line, untransduced 
DCs. D) Specific markers in DCs transduced with LAW34/
RD114/TR using protocol PB or mock transduced, as exam-
ined 2 days PT. E) Flow cytometry analysis of T lymphocytes 
derived from murine spleen cells by ConA/IL-2 stimulation 
and transduced with LAW34/VSV-G (thick line) or LAW34/
RD114/TR (grey area) using DT protocol. Dotted line, 
untransduced T lymphocytes. F) Efficiency of T lymphocyte 
transduction by LAW34/VSV-G and LAW34/RD114/TR 
using the protocols indicated.Page 10 of 13
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different in sequence from the ones previously used [30],
was poorly functional.
2) the genome of lentiviruses is encapsidated through the
mutual recognition of specific RNA sequences (ψ) and
specific viral and cellular proteins [41]. In FIV, ψ is
believed to consist of at least two discontinuous core
regions, the first located upstream the major splice donor
site, the second extending into gag. While later analyses
have located the principal ψ domains within the first 100–
120 nt [31], in early RNA protection experiments, optimal
viral RNA encapsidation was obtained by extending the
gag region to 311 nt [23]. A 310-nt sequence, that in our
FIV encompasses the entire region found to be important
in the above study [23], was then substituted for the 120-
nt sequence present in LA34, but this brought no benefits
and actually impaired nonfeline cell transduction. Again,
the reason(s) for this discrepancy relative to previous
studies was not investigated but it might lie in differences
between the FIV clones used or in the genomic organiza-
tion of the vectors developed. In any case, these results,
together with the reported presence of negative regulatory
sequences upstream and within ψ [31,42] and the consid-
eration that fewer parental virus sequences are present in
a vector the better, made us to decide in favor of the vector
with the shorter ψ.
3) the introduction of the RNA transport element WPRE
into FIV- and HIV-derived vectors has been shown to sta-
bilize and enhance transgene expression [30,43]. When
we introduced this element into LA34 we also observed a
favorable impact on vector performance: the vector thus
modified (LAW34) not only showed higher titers relative
to LA34 but also transduced with enhanced efficiency all
the cell lines. Importantly, the positive effects of WPRE
were most evident in NIH-3T3 cells, suggesting that
LAW34 might be particularly suitable for transducing
murine cells.
We then focused on further optimizing LAW34 for usage
with murine NIH-3T3 cells by modifying external coat
and transduction protocol, two factors known to be as
important as the vector itself for successful gene targeting
and delivery. VSV-G pseudotyping is extremely conven-
ient for vector development and in vitro testing since,
being the cell receptor for VSV a ubiquitous phospholipid
[44], it allows vector access into virtually any cell type, but
this extended host range can be unpractical for vector
usage in vivo where restricted cell targeting is often
required. Moreover, VSV-G pseudotyped vectors have
proved toxic for ex vivo cells and prone to inactivation by
complement [45]. Thus, while in setting up the vector we
had used VSV-G pseudotyped particles, in subsequent
studies, among the many Env glycoproteins available for
pseudotyping retrovirus vectors particles [46], we selected
RD114/TR, derived from the feline endogenous ecotropic
virus RD114, which has a sodium-dependent neutral-
amino-acid transporter as cellular receptor, but having the
cytoplasmatic tail of MLV-A. This chimeric Env, which in
other systems has been shown to substantially increase
vector titers, improve cellular localization and interaction
with Gag [47], resist lysis by human complement and per-
mit transduction of primary human lymphocytes and
stem cells [24], to our knowledge had never been used
with FIV vectors. The choice proved fortunate, because
LAW34 pseudotyped with this Env (LAW34/RD114/TR)
transduced at high efficiency all the cell lines tested and
compared favorably to VSV-G pseudotyping regardless of
the transducing protocol used.
We finally examined the efficiency of LAW34 at transduc-
ing ex vivo murine DCs and T cells using different trans-
duction protocols. The results showed that the vector has
the ability to efficiently transduce both cell types, but that
the Env with which it is pseudotyped is critical for DC
transduction. Indeed, while T cells were transduced to
similar extents regardless of whether the vector was coated
with VSV-G or RD114/TR, DCs were transduced by
LAW34/RD114/TR alone, thus suggesting that previous
unsatisfactorily attempts to efficiently transduce DCs with
FIV vectors [14-16,40] may have been due to the use of
Envs that did not permit proper entry into these cells. Of
note, in agreement with findings showing that DCs trans-
duced with different vectors develop a mature phenotype
[1,6,11], murine DCs transduced with LAW34/RD114/TR
exhibited at least some of the morphological and surface
markers known to accompany DC maturation, thus show-
ing that they were still functional. A further observation of
interest was that LAW34 transduction of DCs and T cells
occurred also in the absence of added facilitating agents,
such as PB, that preferably should be avoided when vec-
tors are used in vivo.
Conclusion
The FIV-derived vector LAW34 has features compatible
with a prospective usage for vaccinal purposes. These
include the small size of the vector that permits to accom-
modate large transgenes, possibly encoding more than
one protein, and the ability to deliver such transgenes into
two key cell types of the immune system. In vitro and in
vivo studies investigating whether transduced DCs can
serve as antigen presenting cells and whether transduced T
cells can be used in prime-boost vaccine experiments are
currently underway.
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